share_log

GSK(GSK.US)达成近15亿欧元协议 开发潜在“best-in-class”mRNA疗法

JRJ Finance ·  Jul 4 10:37

GSK(GSK.US)和CureVac(CVAC.US)宣布,他们已将现有合作重组为一项新的许可协议,使两家公司能够优先投资并专注于各自的mRNA开发活动。根据此协议,CureVac将获得近15亿欧元的款项。

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment